Article Figures & Data
Figures
- Fig. 1.
Global distribution of the 1,358 participants. Among these 1,358 participants, the majority were from mainland China (27%); Taiwan (8%); United States (25%); and Europe (30%), including France, United Kingdom, Spain and others.
- Fig. 2.
High-flow nasal cannula (HFNC) indications. Overall (red bar), postextubation hypoxemia was the top HFNC indication, followed by moderate hypoxemia, mild hypoxemia and postextubation COPD. In North America, more clinicians preferred to use HFNC to treat severe hypoxemia than other areas; whereas, in China, more clinicians used HFNC to facilitate extubation for patients with COPD, and more European clinicians used HFNC to improve or maintain peri-intubation oxygenation.
- Fig. 3.
Aerosol therapy during high-flow nasal cannula (HFNC) treatment. When patients required short-term aerosol treatment during HFNC therapy, 33% of the participants (331/1,014) discontinued HFNC treatment to use a conventional aerosol device, 40% (403/1,014) placed the nebulizer with a mask over the nasal cannula, and 24% (248/1,014) placed the nebulizer in-line within the HFNC circuit. Of the 248 participants who delivered aerosol via HFNC, 40% used a vibrating mesh nebulizer, 30% used an ultrasonic nebulizer, and 28% used a small-volume jet nebulizer.
Tables
Online data supplement
Files in this Data Supplement:
